GLP-1 medications have become a shortcut for a much bigger conversation.
Depending on the headline, they’re either a miracle, a menace, a moral failure, or a cultural threat.
What they almost never are is slowed down.
The coverage moves fast.
People don’t.
And that gap matters.
A Story That Doesn’t Fit Either Side
A journalist recently described her year on a GLP-1 medication.
It didn’t begin with carelessness or vanity.
It began after a year of stress.
A job she hated.
A living situation that wore her down.
Food became comfort.
Weight followed.
When life stabilized, her appetite didn’t.
So she did what many people are now doing.
She used an online provider.
Filled out a questionnaire.
Uploaded photos.
Got prescribed quickly.
At first, it felt like relief.
She ate less.
Lost weight.
No obvious side effects.
Then the dose increased.
Vomiting.
Severe abdominal pain.
Emergency room visits.
Reassurance. Encouragement to continue because the weight loss was “working.”
Eventually, she was diagnosed with gallstones, pancreatitis, and liver stress. Surgery followed.
She’s careful not to claim direct causation. Rapid weight loss alone increases gallstone risk. The science is still evolving.
But the experience was real.
Prolonged.
Frightening.
And not slowed down early enough.
That story doesn’t fit “GLP-1s are amazing.”
It doesn’t fit “GLP-1s are dangerous.”
It sits in the middle.
Which is where most people live.
The Other Side of the Arc
Then there’s what happens after the medication stops.
Karen Lay, 56, described the weeks after coming off Mounjaro as “the worst three weeks of my life.”
The hunger was overwhelming.
Constant.
Relentless.
She went to bed thinking about food.
Woke up thinking about food.
Within a month, she regained weight rapidly. Support from her prescriber was minimal.
Her experience isn’t rare.
Research shows that most people regain a significant portion of the weight within a year after stopping GLP-1 medications. Not because they suddenly lost discipline, but because the biological effects wear off faster than new behaviors stabilize.¹
When appetite suppression disappears, appetite doesn’t just return.
It often rebounds.
That’s not a character flaw.
It’s physiology.
Where the Conversation Keeps Failing
We argue about outcomes.
We skip the transition.
GLP-1s change appetite.
They change satiety.
They change how decisions feel.
For many people, the constant internal negotiation quiets.
Urgency drops.
Food noise fades.
That can be a gift.
But when the noise drops, new skills are required.
Listening replaces resisting.
Awareness replaces force.
And when the medication stops, those skills matter even more.
Most coverage jumps from before to after.
It skips the fragile middle — where people are recalibrating their bodies, their hunger signals, and their identity.
The Danger of Certainty
Some narratives frame GLP-1s as proof that willpower never mattered.
Others frame them as a lazy shortcut.
Both flatten people.
The journalist didn’t ignore her symptoms.
She asked questions.
She sought care.
She trusted systems that told her things were normal.
Karen Lay didn’t lack motivation.
She lacked structured support during a biological transition.
Neither story is about blame.
Both are about pacing.
Medication Changes the Moment. It Doesn’t Remove It.
GLP-1s don’t eliminate choice.
They change the texture of choice.
When appetite quiets, signals become subtler.
When praise is loud, risk can hide.
When weight drops quickly, discomfort is easier to dismiss.
The problem isn’t the medication.
It’s the speed at which we move through the experience.
A Better Question Than “Do GLP-1s Work?”
The better question is simpler:
What helps people slow down enough to notice what’s changing?
Before pain becomes a crisis.
Before hunger becomes panic.
Before weight regain becomes shame.
Medication can help.
Structure can help.
Support can help.
But none of them work well when certainty replaces attention.
Where Clarity Actually Comes From
Clarity doesn’t come from louder opinions or cleaner headlines.
It comes from slowing the moment when decisions are being made.
Especially when things seem to be “working.”
If we talked about GLP-1s that way, fewer people would feel misled.
And more people would feel prepared.
Slow the moment.
Then talk.
If you’re considering GLP-1s, currently using them, or thinking about coming off:
Don’t just ask whether they work.
Ask:
- What support is in place during dose changes?
- What monitoring is happening beyond weight?
- What skills are being built while appetite is quieter?
- What is the transition plan?
Medication may change biology.
But leadership still lives in the moment before the decision.
If you want structure for that moment — not motivation, not rules, but clarity under pressure — you can start here:
Because the goal isn’t to argue about GLP-1s.
It’s to help you lead yourself — whether appetite is loud, quiet, or somewhere in between.
Sources
- BMC Medicine (2022). Weight regain after discontinuation of GLP-1 receptor agonists: meta-analysis of randomized trials.
- NICE (2024). Obesity management guidelines: pharmacotherapy and structured follow-up.
- FDA. Wegovy (semaglutide) and Mounjaro (tirzepatide) prescribing information.
- NIH / NHS. Gallstones and rapid weight loss clinical guidance.
If something here resonated, you can take the next step that feels right for you.
Follow on LinkedIn
Short reflections on health, leadership, and the moments that matter.
Join Optimized Health for Leaders
A private space where thoughtful leaders slow things down and talk honestly about health, energy, and life.
Listen to the podcast
Real conversations about clarity, confidence, and living with more intention.
Work with me, when you’re ready
If you want support that helps you quiet the inner noise and make decisions you trust, we can talk.
